Cabazitaxel
- Generic Name
- Cabazitaxel
- Brand Names
- Jevtana, Cabazitaxel Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C45H57NO14
- CAS Number
- 183133-96-2
- Unique Ingredient Identifier
- 51F690397J
- Background
Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more readily penetrate the blood–brain barrie...
- Indication
用于治疗转移性去势抵抗性前列腺癌患者。
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2021-01-05
- Target Recruit Count
- 120
- Registration Number
- NCT04622761
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT04592237
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.
- Conditions
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT04495179
- Locations
- 🇪🇸
Research Site, Madrid, Spain
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
- Conditions
- Interventions
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 22
- Registration Number
- NCT03934840
- Locations
- 🇺🇸
Thomas Jeferson University, Philadelphia, Pennsylvania, United States
🇺🇸Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8AnemiaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCastration-Resistant Prostate Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AbirateroneDrug: AfatinibBiological: BevacizumabDrug: BicalutamideProcedure: Biospecimen CollectionDrug: BortezomibDrug: CabazitaxelDrug: CabozantinibDrug: CapecitabineDrug: CarboplatinDrug: CelecoxibDrug: CobimetinibDrug: CopanlisibDrug: DabrafenibDrug: DacomitinibDrug: DarolutamideDrug: DasatinibDrug: DoxorubicinBiological: DurvalumabDrug: EnasidenibDrug: EntrectinibDrug: EnzalutamideDrug: ErlotinibDrug: EverolimusDrug: FluorouracilDrug: IdelalisibDrug: ImatinibBiological: IpilimumabDrug: LenvatinibDrug: LeucovorinDrug: LorlatinibDrug: LosartanDrug: Nab-paclitaxelDrug: NeratinibBiological: NivolumabDrug: OlaparibDrug: OxaliplatinDrug: PalbociclibDrug: PanobinostatBiological: PembrolizumabBiological: PertuzumabDrug: PonatinibOther: Quality-of-Life AssessmentDrug: RegorafenibDrug: RuxolitinibDrug: SirolimusDrug: SorafenibDrug: SunitinibDrug: TrametinibBiological: Trastuzumab EmtansineDrug: TretinoinDrug: VemurafenibDrug: VenetoclaxDrug: VismodegibDrug: Vorinostat
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03878524
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Multi-academic Center Study of Xofigo Patients
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 150
- Registration Number
- NCT03419442
- Locations
- 🇺🇸
Bayer US, Whippany, New Jersey, United States
Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel
- Conditions
- Interventions
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 223
- Registration Number
- NCT03419234
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, United States
🇺🇸Sidney and Lois Eskenazi Hospital, Indianapolis, Indiana, United States
A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-08
- Last Posted Date
- 2022-06-13
- Target Recruit Count
- 201
- Registration Number
- NCT03392428
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺Royal North Shore Hospital, Sydney, New South Wales, Australia
CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2017-12-14
- Lead Sponsor
- Consorzio Oncotech
- Target Recruit Count
- 220
- Registration Number
- NCT03356912
- Locations
- 🇮🇹
University Federico II of Naples, Naples, Italy
Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel
- Conditions
- Interventions
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT03295565
- Locations
- 🇳🇱
Deventer Ziekenhuis, Deventer, Netherlands
🇳🇱Academisch medisch centrum Maastricht, Maastricht, Netherlands
🇳🇱Haga Ziekenhuis, The Hague, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.